2016-08-31

RetroSense Therapeutics Receives Patent on Proprietary Method for Restoring Vision using Optogenetics

RetroSense Therapeutics, a privately-held, clinical-stage biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent Application No. 11/036,629, entitled “Method for Augmenting Vision in Persons Suffering from Photoreceptor Cell Degeneration.” RetroSense is the exclusive licensee of this intellectual property for augmenting vision from photoreceptor cell degeneration through a license with Massachusetts General Hospital. This patent broadly covers methods for restoring or improving vision using optogenetic approaches. The allowed claims cover the use of a broad range of opsins and rhodopsins in vision restoration.
Continue reading
Imagine driving down a winding road at dusk, the sky painted in hues of orange and pink. As you approach a curve, the sleek lines of a modern automobile catch your eye. Its design is unmistakable, a blend of retro charm and futuristic elegance... READ MORE

In recent years, the LED display industry has experienced rapid growth, driving fierce market competition. While domestic price wars have intensified, Kinglight has maintained steady progress by relying on its strong technological expertise an... READ MORE